Testing immunotherapy plus chemo for early-stage Hodgkin lymphoma
Treatments studied
Part of Cancer clinical trials.
This trial studies whether adding zimberelimab (an immune system drug) to standard AVD chemotherapy works better for newly diagnosed early-stage Hodgkin lymphoma. It may help improve control of the cancer, especially when it can’t be fully cured with simpler treatment alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with classical Hodgkin lymphoma confirmed by a biopsy (histopathology).
- Your cancer is stage I or II.
- You have at least one measurable tumor spot on scans that can be followed over time.
- You are age 18–45, or you are over 60 (study may treat younger vs older groups differently).
- Your general health ability to do daily activities is ECOG 0–3 and you’re expected to live at least 3 months.
- You are not planned to get an autologous stem cell transplant next.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of the immunotherapy drug sintilimab with chemotherapy (AVD) for children and teens with newly diagnosed low- or intermediate-risk Hodgkin lymphoma. The goal is to see if adding sintilimab can improve outcomes while reducing side effects.
This trial tests a combination of an immunotherapy drug (anti-PD-1 antibody) and radiation therapy for people with newly diagnosed, early-stage classic Hodgkin lymphoma that does not have certain risk factors. The goal is to see if this approach works well and has fewer side effects.
This trial studies a customized immune-based treatment approach for people with early-stage “unfavorable” classical Hodgkin lymphoma who have not had prior treatment. It may help by targeting your lymphoma using an individualized plan based on your case.
This trial tests whether adding pianzumab to standard AVD chemotherapy works better for newly diagnosed advanced classic Hodgkin lymphoma. It may help people control the cancer and prevent it from coming back, and it will compare outcomes while tracking side effects.
This study tests a combination of the immunotherapy drug pembrolizumab with a chemotherapy regimen called GVD for patients whose Hodgkin's lymphoma has not responded or has returned after initial treatment. The goal is to see if this combination works better than standard approaches.
This trial tests adding tislelizumab (an immune medicine) to standard first-line chemotherapy for people age 60 and older with newly diagnosed classic Hodgkin lymphoma. The goal is to improve how well treatment works while adapting the plan for older adults.
Hear when a new Classical Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.